WO2013089478A2 - 신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 - Google Patents
신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 Download PDFInfo
- Publication number
- WO2013089478A2 WO2013089478A2 PCT/KR2012/010900 KR2012010900W WO2013089478A2 WO 2013089478 A2 WO2013089478 A2 WO 2013089478A2 KR 2012010900 W KR2012010900 W KR 2012010900W WO 2013089478 A2 WO2013089478 A2 WO 2013089478A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- opss
- cysteine
- ops
- present
- enzyme
- Prior art date
Links
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 93
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 108030001910 O-phosphoserine sulfhydrylases Proteins 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 48
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims abstract description 48
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 244000005700 microbiome Species 0.000 claims description 31
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 21
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 21
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 21
- 150000001413 amino acids Chemical group 0.000 claims description 18
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000000758 substrate Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- VZXPDPZARILFQX-BYPYZUCNSA-N O-acetyl-L-serine Chemical compound CC(=O)OC[C@H]([NH3+])C([O-])=O VZXPDPZARILFQX-BYPYZUCNSA-N 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 239000005515 coenzyme Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 101710109085 Cysteine synthase, chloroplastic/chromoplastic Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101710138316 O-acetylserine sulfhydrylase Proteins 0.000 description 3
- 241000224527 Trichomonas vaginalis Species 0.000 description 3
- 150000001944 cysteine derivatives Chemical class 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000567139 Aeropyrum pernix Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VHPXSBIFWDAFMB-REOHCLBHSA-N L-2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+][C@H](C([O-])=O)CS1 VHPXSBIFWDAFMB-REOHCLBHSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 101150003203 mec gene Proteins 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- VHPXSBIFWDAFMB-UWTATZPHSA-N D-2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+][C@@H](C([O-])=O)CS1 VHPXSBIFWDAFMB-UWTATZPHSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- -1 mec + and cys0 Chemical compound 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 101150003830 serC gene Proteins 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01065—O-Phosphoserine sulfhydrylase (2.5.1.65)
Definitions
- the present invention relates to a method for producing cysteine or derivatives thereof using novel O-phosphoserine sulfhydrylase.
- Cysteine is an important amino acid in sulfur metabolism of all living organisms, and is used as a precursor for coenzyme A biosynthesis as well as in the synthesis of proteins in vivo, such as hair keratin, glutathione, biotin, methionine and other sulfur-containing metabolites. Cysteine biosynthesis is also known to be closely related to the biosynthesis of other amino acids such as serine, glycine, and methionine. Industrially, cysteines and derivatives thereof are used in the pharmaceutical field (treatment of bronchial diseases), in the cosmetic field (components of hair shampoos and permanent wave lotions) and in the food field (antioxidants, flavor enhancers and dough aids).
- cysteine has been produced by chemical acid-hydrolysis process mainly based on human hair or animal feathers.
- the yield of cysteine extracted from hair is very low (7 ⁇ 8%), and excessive environmental pollution waste is generated by using hydrochloric acid and sulfuric acid used during the extraction process.
- using hair as a raw material can cause disgust to consumers. Due to these problems, the demand for development of environment-friendly cysteine production process has been increased, and thus a method for producing cysteine using microorganisms has been developed.
- cysteine using microorganisms 1) First, a method of biologically converting D, L-ATC using microorganisms is known. However, this method has difficulty in industrialization due to low solubility of the precursors D and L-ATC. 2) Another method is known to produce cysteine by direct fermentation method using E. coli. This method can show intracellular toxicity when excessive accumulation of cysteine in microorganisms, and there is a limit in producing high concentrations of cysteine using microorganisms.
- OAS O-acetyl-serine
- OASS O-acetyl-serine sulfhydrylase
- cysteine can be produced using OASS from microorganisms accumulating OAS and various sulfur donors (US Pat. No. 6,579,705).
- OPS O-phosphoserine sulfhydrylase
- the present inventors have made intensive efforts to develop a method for producing cysteine with high yield, and as a result, have identified a new OPSS having the activity of synthesizing cysteine using OPS as a substrate from various microorganisms, the new OPSS is known trichomonas exhaust blade
- the present invention was completed by confirming that cysteine synthesis activity was increased than that of the OPSS of the lease.
- OPS O-phosphoserine
- OPSS novel O-phosphoserine sulfhydrylase
- O-phosphoserine sulfhydrylase OPSS
- OPSS O-phosphoserine sulfhydrylase
- Figure 1 shows the results of measuring the cysteine conversion at 10 minutes, 30 minutes and 60 minutes using three types of OPSS.
- Figure 2 shows the results of measuring the cysteine conversion for each pH to confirm the pH sensitivity of Dal-OPSS.
- Figure 3 shows the results of measuring the cysteine conversion at 10 minutes, 30 minutes and 60 minutes using OPS fermentation broth and sulfide as three substrates using OPSS.
- Figure 4 shows the results of measuring the cysteine conversion for each temperature of Dal-OPSS.
- the present invention provides O-phosphoserine (O-phosphoserine sulfhydrylase (OPSS) having an amino acid sequence set forth in SEQ ID NO: 1 or 2 or O-phosphoserine (O) in the presence of a microorganism expressing it It provides a method for producing cysteine or derivatives thereof comprising the step of preparing a cysteine or derivatives thereof by reacting -phosphoserine, OPS) with a sulfide.
- OPS O-phosphoserine sulfhydrylase
- O-phosphoserine sulfhydrylase is to provide a thiol group (SH group) to O-phosphoserine (OPS) In other words, it refers to an enzyme having an activity of converting OPS to cysteine.
- the OPSS may be an amino acid sequence set forth in SEQ ID NO: 1 or 2, which is OPSS newly identified by the present inventors.
- the amino acid sequence set forth in SEQ ID NO: 1 or 2 has the activity of OPSS, and can be modified to some extent as long as it maintains the activity.
- amino acid sequences that maintain at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% homology by such artificial modifications are desired in the present invention. As long as it retains activity, it will be readily understood that it is equivalent to the amino acid sequence of the present invention.
- cysteine synthesis activity based on purified OPS and OPS fermentation broth using Dac-OPSS having an amino acid sequence of SEQ ID NO: 1 and Dal-OPSS having an amino acid sequence of SEQ ID NO: 2 was evaluated. As a result, it was confirmed that the high cysteine conversion rate compared to the control Tva-OPSS, OPSS having the amino acid sequence of SEQ ID NO: 1 or 2 can be produced in high yield cysteine (Fig. 1, Fig. 3, Table 3 and Table 4).
- homology refers to the percent sequence similarity between two polypeptide moieties. Sequence similarity from one moiety to another may be determined by known techniques. For example, homology can be determined by aligning sequence information and directly aligning sequence information between two polypeptide molecules using readily available computer programs. Homology can also be determined by hybridizing polynucleotides under conditions of stable double stranding between homologous regions, followed by digestion with single-strand-specific nucleases to determine the size of the digested fragments.
- sequence similarity refers to the degree of identity or correspondence between the base sequence and amino acid sequence of a protein that may or may not share a common evolutionary origin.
- two amino acid sequences have a polypeptide match of at least 21% (preferably at least about 50%, most preferably about 75%, 90%, 95%, 96%, 97) for a given length of amino acid sequence. % Or 99%), are "substantially homologous” or “substantially similar.”
- Substantially homologous sequences can be identified using standard software used in data banks or by comparing the sequences, for example by hybridization experiments used under stringent conditions defined for a particular system. Appropriate hybridization conditions to be defined are within the technical scope (see for example Sambrook et al., 1989, infra).
- cyste conversion refers to a reaction for converting OPS, which is a substrate, into a product cysteine, ie, a conversion of OPS to cysteine to obtain cysteine by the catalytic action of OPSS.
- the term “cysteine conversion” also means the rate at which OPS is converted to cysteine.
- OPSS according to the present invention is shorter than the metabolic pathway using OAS because it undergoes a process of converting OPS to cysteine, and is advantageous for precursor production, unlike the conventional OPSS of coenzymes (mec + and cys0 of M. tuberculosis) Without it, there is an advantage in producing cysteine by OPSS itself.
- OPSS of the present invention may be encoded by a polynucleotide having a nucleotide sequence of SEQ ID NO: 9 to 12.
- the microorganism expressing the OPSS of the present invention may be a microorganism in which the microorganism expressing the OPSS of the present invention or the base sequence encoding the OPSS of the present invention is introduced in the form of a vector or inserted into a chromosome.
- the microorganism expressing the OPSS may further enhance the activity of the OPSS.
- vector refers to any medium for cloning and / or transferring bases using a host cell.
- the vector may be a replica that other DNA fragments can bind to and result in replication of the bound fragments.
- Replication unit refers to any genetic unit (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as a self-unit of DNA replication in vivo, i.e., is replicable by its own regulation. .
- the microorganism expressing the OPSS in the present invention may be a microorganism obtained by the method of transforming the vector containing the OPSS, the transformation method includes any method for introducing a base into the cell, known in the art Suitable standard techniques can be selected and performed. Examples include electroporation, calcium phosphate co-precipitation, retroviral infection, microinjection, DEAE-dextran, and cationic liposomes. cationic liposome), and the like.
- the microorganisms expressing the OPSS can be both prokaryotic or eukaryotic, preferably enterobacteria and microorganisms or coryneform microorganisms, more preferably Escherichia microorganisms, Serratia microorganisms, and the like. E. coli.
- the microorganisms expressing the newly isolated OPSS can be cultured to separate the OPSS from the culture solution. Any method commonly known in the art may be used, and in a specific embodiment of the present invention, a method of culturing microorganisms using a pET expression system manual (Novagen Inc.) and separating Ni-NTA columns was used.
- the OPS used as a substrate of the new OPSS may use not only purified OPS commercially available, but also OPS fermentation broth prepared through fermentation.
- the purified OPS can be purchased, for example, under the P0878 product number from Sigma-Aldrich or CAS407-41-0 product number from Wako.
- the OPS fermentation broth is a microorganism having OPS production capacity, for example, Accession No. KCCM 11103P (CA07-0022 / pCL-prmf-serA * (G336V) -serC; see Republic of Korea Patent Publication No. 10-2012-0041115) It can be prepared by culturing the deposited microorganisms.
- sulfide refers to a compound of sulfur and a more positive element, and is a compound used for preparing cysteine or a derivative thereof for the purpose of the present invention.
- the sulfides are provided in the form of a liquid or a gas due to the difference in pH, pressure, and solubility as well as the solids commonly used in the art, so that sulfides (sulfide, S 2- ), thiolsulfate (S 2 O 3) Any sulfide that can be converted to a thiol group (SH group) in the form of 2- ) and the like can be used.
- Na 2 S, H 2 S, NaSH, (NH 4 ) 2 S and S 2 O 3 can be used.
- Na 2 S was used as the sulfur source.
- the reaction of the present invention is to provide one thiol group in one OPS reactor to produce one cysteine or cysteine derivative, and the amount of sulfide added in the reaction is not limited thereto, but is 0.1 to 0.1 mole of the OPS molar concentration added during the reaction. 3 times is preferable and 1 to 2 times are more preferable.
- the method for allowing the OPSS of the present invention to enable optimal enzyme conversion is applicable to various methods well known in the art. Examples of such methods include, but are not limited to, methods of characterizing OPSS enzymes, preferably OPSS enzyme optimal activity temperature, pH, presence and concentration of substrate inhibition, and thermal stability of OPSS enzyme itself. Methods for determining the optimal conditions of the enzyme conversion reaction, in particular, the optimal OPSS enzyme concentration used in the enzyme conversion reaction, the optimal balance concentration of the substrates used, the preference for sulfides used in the enzyme conversion reaction in addition to the OPS substrate, conversion reaction Buffer affinity used in the experiment, ion influence caused by this, and presence of coenzymes and determination of optimal concentration.
- pyridoxal-5'-phosphate (PLP), dithiothreitol (DTT), or PLP and DTT may be added simultaneously as additional cofactors.
- the cofactors can increase the efficiency in the cysteine conversion reaction, and in one specific embodiment of the present invention, it was confirmed that the cysteine conversion was increased when 0.2 mM PLP, 25 mM DTT, or two cofactors were added simultaneously (Table 5).
- the PLP is not limited thereto, but may preferably be added in an amount of 0.001 to 2 mM, more preferably 0.01 to 1 mM.
- the DTT is not limited thereto but preferably 0.001 to 100 mM may be added, and more preferably 0.01 to 50 mM may be added.
- the method of the present invention may further comprise the step of separating and purifying the cysteine or derivatives thereof produced through the reaction step.
- the desired cysteine can be separated and purified from the reaction solution by using a suitable method known in the art.
- cysteine derivatives from cysteines produced by the methods of the present invention by known chemical synthesis methods.
- Cysteine can be easily synthesized with N-acetylcysteine (NAC) by reacting with an acetylation agent, and with S-Carboxymetylcysteine (SCMC) by reacting with haloacetic acid under basic conditions.
- NAC N-acetylcysteine
- SCMC S-Carboxymetylcysteine
- the cysteine derivative is mainly used as a pharmaceutical raw material for the treatment of antitussives, cough relieving agents, bronchitis, bronchial asthma and sore throat.
- OPSS derived from Trichomonas vaginalis shows activity without coenzyme and shows optimal activity at 37 ° C, unlike OPSS of Aeropyrum pernix which shows optimal activity at 60 ° C. Reported.
- the new OPSS has the amino acid sequences of SEQ ID NOs: 1 and 2, respectively, named Dac-OPSS and Dal-OPSS.
- the novel OPSS having the amino acid sequence of SEQ ID NO: 1 and 2 is encoded by a polynucleotide having a nucleotide sequence of SEQ ID NO: 9 and 10, respectively.
- the two OPSS is not derived from E. coli, it may not be easy to express in E. coli.
- the codon usage of the newly isolated OPSS was optimized. This was performed using Jcat, a codon usage optimization tool (www.jcat.de).
- Jcat a codon usage optimization tool
- SEQID Nos. 11 and 12 with optimal codon usage frequencies of SEQ ID NOs: 9 and 10 for the polynucleotide were obtained.
- the polynucleotides having the nucleotide sequences of SEQ ID NOs: 11 and 12 were synthesized by providing the nucleotide sequences to Genotech Corp., and were supplied in the form of a vector through Topo TA cloning.
- a pET28a (novagen) vector system was constructed, which is commonly used for enzyme expression.
- a total of three OPSS enzyme expression vector names and each template and primer used to prepare the vectors are shown in Table 1 below.
- Gene fragments and vector pET28a obtained by amplifying the respective OPSS genes by PCR and the template and primer combinations were treated with Nde I and Hind III restriction enzymes (37 ° C., 3 hours reaction). Each gene fragment was then inserted into the pET28a vector using conventional ligation techniques. Production of each enzyme expression vector and gene sequence were confirmed by sequencing technique.
- the prepared enzyme expression vector was introduced into E. coli with the DE3 genotype to prepare a strain capable of obtaining a total of three OPSS enzymes.
- Table 1 Enzyme Name Vector icon Used mold Primer used Tva-OPSS pET28a-Tva-OPSS Synthetic DNA SEQ ID NOs: 3 (F) and 4 (R) Dac-OPSS pET28a-Dac-OPSS Synthetic DNA SEQ ID NOs: 5 (F) and 6 (R) Dal-opss pET28a-Dal-OPSS Synthetic DNA SEQ ID NOs: 7 (F) and 8 (R)
- Cysteine synthesis activity of all three OPSS enzymes was measured to determine whether OPS-based cysteine was synthesized. CysM enzyme assay conditions and methods are reported in the literature (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns KE, Baumgart S, Dorrestein PC, Zhai H, McLafferty FW and Begley TP). , J. Am. Chem. Soc., 127: 11602-11603, 2005; Westrop GD, Goodall G, Mottram JC and Coombs GH, J. Biol. Chem., 281: 25062-25075, 2006). Cited. Conditions for measuring enzyme activity are shown in Table 2 below.
- the reaction solution except for the enzyme was incubated at 37 ° C. for 5 minutes, and then 50 ⁇ g of purified OPSS was added thereto and reacted at 37 ° C., 100 ml of the enzyme reaction solution was mixed with time and mixed with 100 ml of 33.2% TCA to stop the reaction. .
- the concentration of cysteine in the enzyme reaction solution was quantified by measuring absorbance at OD 560 wavelength by Gaitonde method.
- Figure 1 and Table 3 shows the cysteine synthesis activity of the three OPSS, the cysteine synthesis titers of the OPSS was evaluated by comparing the cysteine conversion rate by reaction time.
- Tva-OPSS has the activity of synthesizing cysteine using OPS as a substrate.
- the cysteine synthesis activity of the new OPSS Dac-OPSS and Dal-OPSS was confirmed for the first time.
- the use of Dac-OPSS and Dal-OPSS increased the cysteine conversion, especially in the case of Dal-OPSS was confirmed that the activity is significantly high.
- the highest activity was shown between pH 7.0 ⁇ 7.4, the highest activity condition is Tris-HCl (pH 7.0), Na-citrate, almost no activity in Na-carbonate buffer .
- the optimum pH for each buffer was different.
- the serB and defect in E. coli strain W3110, a mutant serA * KCCM is introduced with the OPS-producing ability 11103P (CA07-0022 / pCL-prmf- serA * (G336V) - serC; Republic of Korea Patent Publication No. 10-2012-0041115 No. ) was plated in MMYE solid medium and incubated overnight in a 30 ° C. incubator. Strains incubated overnight in MMYE solid medium were inoculated with one platinum in 25 ml titer medium and then incubated for 48 hours in an incubator at 30 ° C. and 200 rpm.
- the OPS fermentation broth prepared by the above method was used to determine the cysteine conversion rate of Tva-OPSS, Dac-OPSS and Dal-OPSS.
- a cysteine conversion reaction was performed at 37 ° C. with 50 ⁇ g / ml of each OPSS concentration under 5.4 mM OPS fermentation broth, 10 mM Na 2 S, and 0.2 mM PLP.
- the resulting cysteine was quantified by the Gaitonde method.
- 3 and Table 4 show the cysteine conversion rate of the three OPSS at 37 °C, the highest conversion rate when using the Dal-OPSS of the three OPSS in the conversion reaction conditions.
- the cysteine conversion rate according to the presence of PLP (pyridoxal-5'-phosphate) and DTT (dithiothreitol) was confirmed using Dal-OPSS.
- PLP pyridoxal-5'-phosphate
- DTT dithiothreitol
- the cysteine conversion in the experimental group to which PLP and DTT was added was increased by 2.4 times compared to the control group to which PLP and DTT were not added.
- the cysteine conversion was increased also in the experimental group to which PLP or DTT was added alone. That is, it was confirmed that PLP and DTT act positively on the reaction upon cysteine conversion.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
효소명 | 벡터명 | 사용한 주형 | 사용한 프라이머 |
Tva-OPSS | pET28a-Tva-OPSS | 합성 DNA | 서열번호 3(F) 및 4(R) |
Dac-OPSS | pET28a-Dac-OPSS | 합성 DNA | 서열번호 5(F) 및 6(R) |
Dal-OPSS | pET28a-Dal-OPSS | 합성 DNA | 서열번호 7(F) 및 8(R) |
Stock sol'n | Final Conc. | Blank | OPSS |
6xhis-enzyme | - | 40 (50 ㎍) | |
1 M HEPES(pH7.4) | 100 mM HEPES | 100 | 100 |
0.5 M Na2S | 10 mM Na2S | 20 | 20 |
10 mM PLP | 0.2 mM PLP | 20 | 20 |
100 mM OPS | 5 mM OPS | 0 | 50 |
DW | 790 | 750 | |
Total | 1000 | 1000 |
시스테인 전환율(%) | |||
10분 | 30분 | 60분 | |
Tva-OPSS | 5.94 | 11.48 | 19.32 |
Dac-OPSS | 19.47 | 26.47 | 40.26 |
Dal-OPSS | 94.98 | 95.52 | 98.65 |
시스테인 전환율(%) | |||
10분 | 30분 | 60분 | |
Tva-OPSS | 10.23 | 15.62 | 17.44 |
Dac-OPSS | 10.87 | 17.43 | 21.11 |
Dal-OPSS | 8.93 | 29.88 | 38.64 |
Dal-OPSS | 시스테인 전환율(%) |
(-) PLP, (-) DTT | 12.88 |
(+) PLP, (-) DTT | 20.15 |
(-) PLP, (+) DTT | 24.32 |
(+) PLP, (+) DTT | 31.54 |
Claims (7)
- 서열번호 1 또는 2로 기재된 아미노산 서열을 가지는 O-포스포세린 설프하이드릴라아제(O-phosphoserine sulfhydrylase, OPSS), 또는 이를 발현하는 미생물의 존재 하에, O-포스포세린(O-phosphoserine, OPS)을 황화물과 반응시켜 시스테인 또는 이의 유도체를 제조하는 단계를 포함하는, 시스테인 또는 이의 유도체의 생산방법.
- 제1항에 있어서, 상기 OPSS는 서열번호 9 내지 12로 이루어진 군에서 선택되는 염기서열을 가지는 폴리뉴클레오타이드에 의해 코딩되는 것인 방법.
- 제1항에 있어서, 상기 OPS는 정제된 OPS 또는 OPS를 포함하는 미생물의 발효액인 것인 방법.
- 제1항에 있어서, 상기 황화물은 Na2S, H2S, NaSH, (NH4)2S 및 S2O3로 이루어진 군에서 선택되는 것인 방법.
- 제1항에 있어서, 상기 황화물의 첨가량은 반응시 첨가되는 OPS 몰 농도의 0.1 내지 3배인 것인 방법.
- 제1항에 있어서, 상기 반응시 보조인자로서 0.001 내지 2 mM의 PLP(pyridoxal-5'-phosphate) 또는 0.001 내지 100 mM의 DTT(dithiothreitol)를 추가로 첨가하는 것인 방법.
- 제1항에 있어서, 상기 시스테인 또는 이의 유도체를 분리 및 정제하는 단계를 추가로 포함하는 것인 방법.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014547104A JP5860550B2 (ja) | 2011-12-15 | 2012-12-14 | 新規なo−ホスホセリンスルフヒドリラーゼを用いたシステイン又はその誘導体の製造方法 |
CA2859125A CA2859125C (en) | 2011-12-15 | 2012-12-14 | Method for preparing cysteine or a derivative thereof using a novel o-phosphoserine sulfhydrylase |
BR122019023670-4A BR122019023670B1 (pt) | 2011-12-15 | 2012-12-14 | Método para a preparação de cisteína ou de um derivado desta usando uma nova ofosfoserina sulfidrilase |
CN201280067058.7A CN104039963B (zh) | 2011-12-15 | 2012-12-14 | 利用新o-磷酸丝氨酸巯解酶生产半胱氨酸或其衍生物的方法 |
BR112014014762-0A BR112014014762B1 (pt) | 2011-12-15 | 2012-12-14 | Método para a preparação de cisteína ou de um derivado desta usando uma nova o- fosfoserina sulfidrilase |
RU2014125851/10A RU2579689C1 (ru) | 2011-12-15 | 2012-12-14 | Способ получения цистеина или его производного с использованием новой о-фосфосеринсульфгидрилазы |
EP12858268.1A EP2792748B1 (en) | 2011-12-15 | 2012-12-14 | Method for preparing cysteine or a derivative thereof using a novel o-phosphoserine sulfhydrylase |
ES12858268.1T ES2634683T3 (es) | 2011-12-15 | 2012-12-14 | Método de preparación de cisteína o de un derivado de la misma utilizando una nueva O-fosfoserina sulfhidrilasa |
US14/365,571 US9243268B2 (en) | 2011-12-15 | 2012-12-14 | Method for preparing cysteine or a derivative thereof using a novel O-phosphoserine sulfhydrylase |
PH12014501353A PH12014501353B1 (en) | 2011-12-15 | 2014-06-13 | Method for preparing cysteine or a derivative thereof using a novel o-phosphoserine sulfhydrylase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110135665A KR101404376B1 (ko) | 2011-12-15 | 2011-12-15 | 신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 |
KR10-2011-0135665 | 2011-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013089478A2 true WO2013089478A2 (ko) | 2013-06-20 |
WO2013089478A3 WO2013089478A3 (ko) | 2013-08-22 |
Family
ID=48613316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/010900 WO2013089478A2 (ko) | 2011-12-15 | 2012-12-14 | 신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9243268B2 (ko) |
EP (1) | EP2792748B1 (ko) |
JP (1) | JP5860550B2 (ko) |
KR (1) | KR101404376B1 (ko) |
CN (1) | CN104039963B (ko) |
BR (2) | BR112014014762B1 (ko) |
CA (2) | CA2859125C (ko) |
ES (1) | ES2634683T3 (ko) |
MY (2) | MY164371A (ko) |
PH (1) | PH12014501353B1 (ko) |
RU (1) | RU2579689C1 (ko) |
WO (1) | WO2013089478A2 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019013570A2 (ko) | 2017-07-13 | 2019-01-17 | 씨제이제일제당 (주) | 인산을 발효액 또는 발효 폐액으로부터 회수 및 재사용하는 방법 |
WO2019151769A1 (en) | 2018-01-31 | 2019-08-08 | Cj Cheiljedang Corporation | Method for preparing natural l-cysteine hydrochloride hydrate crystals by continuous chromatography |
WO2019151770A1 (en) | 2018-01-31 | 2019-08-08 | Cj Cheiljedang Corporation | Method for preparing natural l-cysteine crystals by continuous chromatography |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101677328B1 (ko) * | 2014-08-12 | 2016-11-18 | 씨제이제일제당 (주) | O-포스포세린 생산 미생물 및 이를 이용한 o-포스포세린 또는 l-시스테인 생산 방법 |
KR101694632B1 (ko) * | 2015-09-11 | 2017-01-10 | 씨제이제일제당 (주) | 신규 o-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
KR101825310B1 (ko) | 2016-12-29 | 2018-03-15 | 씨제이제일제당 (주) | O-포스포세린을 생산하는 에스케리키아 속 미생물 및 이를 이용한 o-포스포세린 또는 l-시스테인을 생산하는 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579705B2 (en) | 2001-04-04 | 2003-06-17 | Consortium Fur Elektrochemische Industrie Gmbh | Process for preparing non-proteinogenic L-amino acids |
KR20120041115A (ko) | 2010-10-20 | 2012-04-30 | 씨제이제일제당 (주) | O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1299128C (en) | 1986-11-19 | 1992-04-21 | Tooru Miyahara | Method of producing l-cystine |
RU2279477C2 (ru) * | 2003-12-05 | 2006-07-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | Мутантная серинацетилтрансфераза, фрагмент днк, кодирующий мутантную серинацетилтрансферазу (варианты), бактерия, принадлежащая к роду escherichia, - продуцент l-цистеина, и способ продукции l-цистеина |
DE102004035052A1 (de) | 2004-07-20 | 2006-02-16 | Basf Ag | Mikroorganismen zur Herstellung von schwefelhaltigen Verbindungen |
JP2006304673A (ja) * | 2005-04-28 | 2006-11-09 | National Institute Of Advanced Industrial & Technology | システイン合成酵素のホスホセリンに対する基質特異性を高める方法 |
CA2611513A1 (en) * | 2005-06-17 | 2006-12-28 | Microbia, Inc. | Improved amino acid and metabolite biosynthesis |
-
2011
- 2011-12-15 KR KR1020110135665A patent/KR101404376B1/ko active IP Right Grant
-
2012
- 2012-12-14 CA CA2859125A patent/CA2859125C/en active Active
- 2012-12-14 WO PCT/KR2012/010900 patent/WO2013089478A2/ko active Application Filing
- 2012-12-14 ES ES12858268.1T patent/ES2634683T3/es active Active
- 2012-12-14 CN CN201280067058.7A patent/CN104039963B/zh active Active
- 2012-12-14 EP EP12858268.1A patent/EP2792748B1/en active Active
- 2012-12-14 BR BR112014014762-0A patent/BR112014014762B1/pt active IP Right Grant
- 2012-12-14 MY MYPI2014001730A patent/MY164371A/en unknown
- 2012-12-14 CA CA2914131A patent/CA2914131C/en active Active
- 2012-12-14 US US14/365,571 patent/US9243268B2/en active Active
- 2012-12-14 RU RU2014125851/10A patent/RU2579689C1/ru active
- 2012-12-14 JP JP2014547104A patent/JP5860550B2/ja active Active
- 2012-12-14 MY MYPI2016000752A patent/MY176977A/en unknown
- 2012-12-14 BR BR122019023670-4A patent/BR122019023670B1/pt active IP Right Grant
-
2014
- 2014-06-13 PH PH12014501353A patent/PH12014501353B1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579705B2 (en) | 2001-04-04 | 2003-06-17 | Consortium Fur Elektrochemische Industrie Gmbh | Process for preparing non-proteinogenic L-amino acids |
KR20120041115A (ko) | 2010-10-20 | 2012-04-30 | 씨제이제일제당 (주) | O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법 |
Non-Patent Citations (3)
Title |
---|
BURNS KE; BAUMGART S; DORRESTEIN PC; ZHAI H; MCLAFFERTY FW; BEGLEY TP, J. AM. CHEM. SOC., vol. 127, 2005, pages 11602 - 11603 |
MINO K; ISHIKAWA K, FEBS LETTERS, vol. 551, 2003, pages 133 - 138 |
WESTROP GD; GOODALL G; MOTTRAM JC; COOMBS GH, J. BIOL. CHEM., vol. 281, 2006, pages 25062 - 25075 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019013570A2 (ko) | 2017-07-13 | 2019-01-17 | 씨제이제일제당 (주) | 인산을 발효액 또는 발효 폐액으로부터 회수 및 재사용하는 방법 |
WO2019151769A1 (en) | 2018-01-31 | 2019-08-08 | Cj Cheiljedang Corporation | Method for preparing natural l-cysteine hydrochloride hydrate crystals by continuous chromatography |
WO2019151770A1 (en) | 2018-01-31 | 2019-08-08 | Cj Cheiljedang Corporation | Method for preparing natural l-cysteine crystals by continuous chromatography |
US11427537B2 (en) | 2018-01-31 | 2022-08-30 | Cj Cheiljedang Corporation | Method for preparing natural L-cysteine hydrochloride hydrate crystals by continuous chromatography |
US11708591B2 (en) | 2018-01-31 | 2023-07-25 | Cj Cheiljedang Corporation | Method for preparing natural L-cysteine crystals by continuous chromatography |
Also Published As
Publication number | Publication date |
---|---|
US9243268B2 (en) | 2016-01-26 |
BR112014014762B1 (pt) | 2021-06-29 |
MY176977A (en) | 2020-08-28 |
EP2792748A2 (en) | 2014-10-22 |
PH12014501353A1 (en) | 2014-09-22 |
RU2579689C1 (ru) | 2016-04-10 |
ES2634683T3 (es) | 2017-09-28 |
US20150004657A1 (en) | 2015-01-01 |
PH12014501353B1 (en) | 2014-09-22 |
CA2859125A1 (en) | 2013-06-20 |
WO2013089478A3 (ko) | 2013-08-22 |
CA2859125C (en) | 2018-05-01 |
CA2914131C (en) | 2018-05-01 |
MY164371A (en) | 2017-12-15 |
BR122019023670B1 (pt) | 2021-06-29 |
BR112014014762A2 (ko) | 2018-05-22 |
JP2015500039A (ja) | 2015-01-05 |
JP5860550B2 (ja) | 2016-02-16 |
CN104039963A (zh) | 2014-09-10 |
BR112014014762A8 (pt) | 2019-11-19 |
CA2914131A1 (en) | 2013-06-20 |
CN104039963B (zh) | 2016-08-31 |
EP2792748B1 (en) | 2017-04-26 |
EP2792748A4 (en) | 2015-08-05 |
KR20130068135A (ko) | 2013-06-25 |
KR101404376B1 (ko) | 2014-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5789670B2 (ja) | O−ホスホセリンスルフヒドリラーゼ変異体及びそれを用いたシステインの生成方法 | |
WO2013089478A2 (ko) | 신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 | |
EP1382684B1 (de) | Verfahren zur fermentativen Herstellung von Aminosäuren und Aminosäure-Derivaten der Phosphoglycerat-Familie | |
WO2014182125A1 (en) | Novel o-phosphoserine export protein and the method of producing o-phosphoserine using the same | |
WO2012087038A2 (ko) | 신규 o-아세틸호모세린 설피드릴라아제 또는 이의 변이체 및 이를 이용한 메치오닌 전환 방법 | |
WO2014182119A1 (en) | Novel rhtb protein variants and the method of producing o-phosphoserine using the same | |
WO2017122931A1 (ko) | L-시스테인 생산용 변이미생물 및 이를 이용한 l-시스테인의 제조방법 | |
WO2017065529A1 (ko) | O-아세틸호모세린 설피드릴라제 변이체 및 이를 이용한 l-메치오닌 제조 방법 | |
KR101404325B1 (ko) | 신규 o-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법 | |
WO2012118318A2 (ko) | 비천연 아미노산 생산 균주 및 이를 이용한 비천연 아미노산의 제조 방법 | |
WO2017065457A1 (ko) | L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법 | |
CN105189734A (zh) | 提高l-半胱氨酸生产能力的属于肠杆菌科的细菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12858268 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014547104 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2859125 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14365571 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122019023670 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2012858268 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012858268 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014125851 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014014762 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014014762 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140616 |